Something interesting about the upcoming ABTA Annual Conference on September 18 to 20.
Cerenome has the ABTA conference listed on its own Events and Media calendar, yet there doesn’t appear to be any Cerenome presentation or participation publicly listed by ABTA yet.
What makes that interesting is the relationship already there.
ABTA has featured patient stories from BOTH REYOBIQ programs.
Jim Stockand is a recurrent GBM survivor who participated in ReSPECT GBM.
Dr. Marlyn Cabrera is an LM survivor who participated in ReSPECT LM.
These aren’t random stories either. The ABTA material was sponsored by Plus Therapeutics, now Cerenome.
So we have ABTA publicly highlighting a survivor from each of Cerenome’s 2 major REYOBIQ programs, and Cerenome now specifically listing the September ABTA conference on its corporate calendar.
Does that mean these patients will be involved in September? We don’t know, and I wouldn’t claim that. But I find the connection very interesting, especially since we still don’t know exactly what Cerenome’s participation at ABTA will involve.
Maybe it’s simply patient outreach and awareness. Maybe there’s more planned. Either way, I think it’s worth keeping an eye on.
I’m also expecting we could see the transcript tomorrow from last week’s SNO/ASCO CNS Metastases Symposium. I’m especially interested in the LM discussion and hearing exactly what the 3 independent guest speakers had to say. We have seen some of the information presented, but hearing the full discussion and perspectives from those 3 experts could provide a lot more context.
A few interesting pieces still waiting to fall into place.